Robin Harper Cowie Sells 24,664 Shares of Biodesix, Inc. (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) CFO Robin Harper Cowie sold 24,664 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $22,690.88. Following the transaction, the chief financial officer now owns 246,460 shares in the company, valued at approximately $226,743.20. This represents a 9.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Biodesix Stock Down 1.1 %

BDSX traded down $0.01 during trading on Wednesday, hitting $0.94. The stock had a trading volume of 170,859 shares, compared to its average volume of 460,809. The stock has a 50 day simple moving average of $1.26 and a two-hundred day simple moving average of $1.49. The company has a market capitalization of $136.74 million, a PE ratio of -2.41 and a beta of 1.06. Biodesix, Inc. has a twelve month low of $0.86 and a twelve month high of $2.04. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BDSX. Barclays PLC increased its holdings in Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after buying an additional 21,179 shares in the last quarter. HighTower Advisors LLC grew its position in shares of Biodesix by 17.1% in the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock valued at $236,000 after purchasing an additional 22,500 shares during the period. Geode Capital Management LLC grew its stake in Biodesix by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock valued at $1,266,000 after acquiring an additional 22,623 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Biodesix during the 3rd quarter valued at about $262,000. Finally, Stephens Inc. AR purchased a new stake in Biodesix during the 4th quarter valued at about $303,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.